Though currently only FDA-approved for type 2 diabetes and obesity, the FDA does not restrict people with type 1 from using these drugs
This SLR identified only one study formally assessing treatment sequencing (RECAP), in which no significant difference in kidney outcomes was observed, based on whether SGLT2i or GLP-1 RA therapy was initiated first [17]
The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations
abcam) in 20 mM HEPES (pH 7.4) and 1.0 mM C14 betaine micelle buffer were titrated with increasing concentrations of FITC-tagged IR domain-binding peptide (ITP) or FITC-tagged scrambled ITP
Individual results vary and depend on factors including starting weight, program adherence, diet, exercise, and the clinical recommendations of the treating provider
J Biomed Sci 2009;16(1):4